Berg Selina Kikkenborg, Wallach-Kildemoes Helle, Rasmussen Line Ryberg, Nygaard Ulrikka, Bundgaard Henning, Petersen Maria Nivi Schmidt, Hammer Cecilie Bech, Ersbøll Annette Kjær, Thygesen Lau Caspar, Nielsen Susanne Dam, Christensen Anne Vinggaard
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Inge Lehmanns Vej 7, 2100 Copenhagen, Denmark.
Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.
Vaccines (Basel). 2022 Nov 4;10(11):1863. doi: 10.3390/vaccines10111863.
This study investigated self-reported short- and long-term symptoms among adolescents receiving the BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2 and those who did not. A retrospective cohort study based on Danish national survey (collected between 20 July and 15 September 2021) and register data was conducted. Differences in short-term (<14 days) and long-term (>two months) symptoms were explored using logistic regression adjusted for confounders. A total of 747 vaccinated (first dose n = 326; second dose n = 421) and 6300 unvaccinated adolescents were included in analyses of short-term symptoms and 32 vaccinated and 704 unvaccinated adolescents in long-term symptom analyses. In the first 14 days after the first and second vaccine dose the most reported symptoms included headache and muscle or joint symptoms. In both vaccinated and unvaccinated adolescents, the 15−19-year-olds reported significantly higher proportions of all symptoms compared to the 12−14-year-olds. After the second vaccine dose vaccinated 12−14-year-olds reported significantly more headache in adjusted analyses (OR 2.20 (95% CI 1.24; 3.90)). Among the 15−19-year-olds, significantly more vaccinated adolescents reported gastrointestinal symptoms (1.38 (1.06; 1.81)), headache (1.66 (1.24; 2.22)), and tiredness (1.44 (1.08; 1.93)). No differences were found in long-term symptoms. Vaccinated adolescents reported significantly more short-term symptoms including headache, tiredness, and gastrointestinal symptoms after the second vaccine dose than unvaccinated adolescents. Long-term symptom results should be interpreted with caution due to limited sample size.
本研究调查了接种针对SARS-CoV-2的BNT162b2（辉瑞/生物科技公司）疫苗的青少年与未接种疫苗的青少年自我报告的短期和长期症状。基于丹麦全国调查（2021年7月20日至9月15日收集）和登记数据进行了一项回顾性队列研究。使用对混杂因素进行调整的逻辑回归探讨短期（<14天）和长期（>两个月）症状的差异。共有747名接种疫苗者（第一剂n = 326；第二剂n = 421）和6300名未接种疫苗的青少年纳入短期症状分析，32名接种疫苗者和704名未接种疫苗的青少年纳入长期症状分析。在第一剂和第二剂疫苗接种后的前14天，最常报告的症状包括头痛以及肌肉或关节症状。在接种疫苗和未接种疫苗的青少年中，15 - 19岁的青少年报告的所有症状比例均显著高于12 - 14岁的青少年。在调整分析中，接种第二剂疫苗后，12 - 14岁接种疫苗的青少年报告头痛的比例显著更高（比值比2.20（95%置信区间1.24；3.90））。在15 - 19岁的青少年中，接种疫苗的青少年报告胃肠道症状（1.38（1.06；1.81））、头痛（1.66（1.24；2.22））和疲劳（1.44（1.08；1.93））的比例显著更高。在长期症状方面未发现差异。接种疫苗的青少年在接种第二剂疫苗后报告的短期症状（包括头痛、疲劳和胃肠道症状）显著多于未接种疫苗的青少年。由于样本量有限，长期症状结果应谨慎解读。
